Brepocitinib VALOR Trial Shows Significant Benefit Brepocitinib 30 mg daily produced a 60% responder rate vs 30% placebo at week 16; NEJM published VALOR results on Mar 28, 2026, reshaping dermatomyositis treatment debate.

Brepocitinib VALOR Trial Shows Significant Benefit: Brepocitinib 30 mg daily produced a 60% responder rate vs 30% placebo at week 16; NEJM published VALOR results on Mar 28, 2026, reshaping dermatomyositis… 👈 Read full analysis #Brepocitinib #VALORTrial #Dermatomyositis #ClinicalTrials #NEJM